Personalized medicine: Time for one-person trials.
J. Craig Venter Institute in La Jolla, California, USA. He is also professor at the University of California, San Diego, and at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona, USA.
Nicholas J
NJ
Schork
D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D001549:Benzamides / Q000494:pharmacology; D015415:Biomarkers / Q000032:analysis; D000068818:Cetuximab; D002986:Clinical Trials as Topic / Q000379:methods* / Q000639:trends*; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000494:pharmacology; D010597:Pharmacogenetics / Q000639:trends; D010879:Piperazines / Q000494:pharmacology; D057285:Precision Medicine / Q000379:methods* / Q000639:trends*; D011743:Pyrimidines / Q000494:pharmacology; D012107:Research Design; D018401:Sample Size; D013449:Sulfonamides / Q000494:pharmacology; D000077484:Vemurafenib
D061067:Antibodies, Monoclonal, Humanized; D001549:Benzamides; D015415:Biomarkers; D007211:Indoles; D010879:Piperazines; D011743:Pyrimidines; D013449:Sulfonamides; D000077484:Vemurafenib; D000068877:Imatinib Mesylate; D000068818:Cetuximab